Edition:
India

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

13.93USD
9:05pm IST
Change (% chg)

$0.18 (+1.31%)
Prev Close
$13.75
Open
$13.96
Day's High
$14.25
Day's Low
$13.81
Volume
12,053
Avg. Vol
15,390
52-wk High
$16.59
52-wk Low
$8.80

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

Summit Therapeutics DMD treatment gets U.S. FDA fast track status
Monday, 26 Sep 2016 

Summit Therapeutics Plc :Receives fast track designation from U.S. FDA for Ezutromid in treatment of Duchenne muscular dystrophy.  Full Article

Summit receives fast track designation from FDA for Ezutromid
Monday, 26 Sep 2016 

Summit Therapeutics Plc :Summit receives fast track designation from U.S. FDA for Ezutromid in the treatment of duchenne muscular dystrophy.  Full Article

Summit reports positive phase 1 new formulation data for DMD Candidate Ezutromid
Tuesday, 9 Aug 2016 

Summit Therapeutics Plc : Summit reports positive phase 1 new formulation data and outlines route to market strategy for DMD Candidate Ezutromid .Initial F3 formulation 24-week biopsy data are now expected Q2/Q3 2017.  Full Article

First patient enrolled in Summit's PhaseOut DMD
Friday, 17 Jun 2016 

Summit Therapeutics : Anticipates reporting data periodically during trial with 24-week muscle biopsy data from first group of patients enrolled expected in jan 2017 .First patient enrolled in Summit's PhaseOut DMD, a phase 2 clinical trial of ezutromid in boys with DMD.  Full Article

Summit Therapeutics says Ridinilazole being prepared to enter Phase 3 trials
Thursday, 2 Jun 2016 

Summit Therapeutics : Summit Therapeutics reports financial results for the first quarter ended 30 April 2016 and operational progress . Loss for three months ended 30 April 2016 of £5.2 million compared to a loss of £3.4 million for three months ended 30 April 2015 . Summit Therapeutics Plc says cash and cash equivalents at 30 April 2016 of £10.0 million compared to £16.3 million at 31 January 2016 .Summit Therapeutics Plc says Ridinilazole being prepared to enter phase 3 clinical trials.  Full Article

No consensus analysis data available.